A Salt Lake City biotech company with a patent for a key breast cancer test is getting a bad reputation in Canada and Europe. Organiza-tions in both countries are challenging its patents.
Myriad Genetics, Inc., a ten-year-old biotech venture, has patents covering the BRCA1 and BRCA2 genes, mutations in which are believed to cause at least 10 percent of all breast cancer. The patents cover tests for these mutations.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
